Diana M. Brainard

26.8k total citations · 3 hit papers
189 papers, 7.6k citations indexed

About

Diana M. Brainard is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Diana M. Brainard has authored 189 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Hepatology, 107 papers in Epidemiology and 88 papers in Infectious Diseases. Recurrent topics in Diana M. Brainard's work include Hepatitis C virus research (141 papers), HIV/AIDS drug development and treatment (81 papers) and Liver Disease Diagnosis and Treatment (74 papers). Diana M. Brainard is often cited by papers focused on Hepatitis C virus research (141 papers), HIV/AIDS drug development and treatment (81 papers) and Liver Disease Diagnosis and Treatment (74 papers). Diana M. Brainard collaborates with scholars based in United States, Germany and France. Diana M. Brainard's co-authors include John G. McHutchison, Evguenia S. Svarovskaia, Robert H. Hyland, Hongmei Mo, Hadas Dvory‐Sobol, Edward Gane, William T. Symonds, Eric Lawitz, G. Mani Subramanian and Michael D. Miller and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Diana M. Brainard

183 papers receiving 7.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

2014 592 citations Robert H. Hyland, Evguenia S. Svarovskaia et al. profile →
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

2019 468 citations Chloe Orkin, Xuelian Wei et al. profile →
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

2022 164 citations Edwin DeJesus, Hadas Dvory‐Sobol et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana M. Brainard United States	50	5.7k	5.3k	2.6k	911	663	189	7.6k
Kenneth E. Sherman United States	44	6.7k 1.2×	5.8k 1.1×	2.2k 0.8×	690 0.8×	459 0.7×	250	8.7k
Douglas T. Dieterich United States	49	6.9k 1.2×	7.0k 1.3×	2.3k 0.9×	711 0.8×	590 0.9×	258	9.3k
Massimo Puoti Italy	47	7.0k 1.2×	6.6k 1.3×	2.5k 0.9×	651 0.7×	571 0.9×	263	9.1k
Stefan Mauss Germany	40	4.3k 0.8×	4.1k 0.8×	1.8k 0.7×	683 0.7×	503 0.8×	191	5.6k
Yves Benhamou France	46	7.0k 1.2×	7.0k 1.3×	1.6k 0.6×	342 0.4×	331 0.5×	101	8.2k
Pablo Labarga Spain	36	2.1k 0.4×	2.2k 0.4×	2.0k 0.8×	849 0.9×	617 0.9×	137	3.8k
Juan Macı́as Spain	38	3.1k 0.5×	3.1k 0.6×	1.3k 0.5×	530 0.6×	489 0.7×	223	4.5k
Philippe Halfon France	48	4.1k 0.7×	4.7k 0.9×	2.4k 0.9×	1.6k 1.8×	198 0.3×	223	7.8k
Arthur Y. Kim United States	38	3.3k 0.6×	2.7k 0.5×	1.2k 0.5×	658 0.7×	132 0.2×	121	4.9k
Andri Rauch Switzerland	34	1.7k 0.3×	1.9k 0.4×	1.7k 0.6×	1.0k 1.1×	479 0.7×	145	3.8k

Countries citing papers authored by Diana M. Brainard

Since Specialization

Citations

This map shows the geographic impact of Diana M. Brainard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana M. Brainard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana M. Brainard more than expected).

Fields of papers citing papers by Diana M. Brainard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana M. Brainard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana M. Brainard. The network helps show where Diana M. Brainard may publish in the future.

Co-authorship network of co-authors of Diana M. Brainard

This figure shows the co-authorship network connecting the top 25 collaborators of Diana M. Brainard. A scholar is included among the top collaborators of Diana M. Brainard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana M. Brainard. Diana M. Brainard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Müller, Walther, David W. Kimberlin, Ana Méndez‐Echevarría, et al.. (2021). Safety and efficacy of remdesivir in a pediatric covid-19 population. 29(1). 237–237. 3 indexed citations

Orkin, Chloe, Faïza Ajana, Cissy Kityo, et al.. (2021). Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 88(4). 393–398. 5 indexed citations

Hagins, Debbie, Princy Kumar, Michael S. Saag, et al.. (2020). 1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV. Open Forum Infectious Diseases. 7(Supplement_1). S552–S553. 1 indexed citations

Eron, Joseph J., Aimee Wilkin, Moti Ramgopal, et al.. (2020). 1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis. Open Forum Infectious Diseases. 7(Supplement_1). S529–S530. 6 indexed citations

Chaturvedi, Nimisha, Evguenia S. Svarovskaia, Hongmei Mo, et al.. (2019). Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. eLife. 8. 11 indexed citations

Uchida, Yoshihito, Shugo Nakamura, Kayoko Naiki, et al.. (2018). Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. Scientific Reports. 8(1). 8818–8818. 11 indexed citations

Lim, Seng Gee, Rosmawati Mohamed, Phuong Le, et al.. (2018). IDDF2018-ABS-0112 Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1–6 hcv infected population from singapore, malaysia, thailand, and vietnam: results from a phase 3, clinical trial. A100.1–A100. 2 indexed citations

Sise, Meghan E., Naim Alkhouri, Brian B. Borg, et al.. (2017). Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR ≤ 30 mL/min): a case series. Journal of Hepatology. 66(1). S721–S722. 1 indexed citations

Yoshida, Eric M., Paul Y. Kwo, Kosh Agarwal, et al.. (2017). Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.. Annals of Hepatology. 16(3). 375–381. 4 indexed citations

10.

Camus, Grégory, Byoung Geun Han, Tarik Asselah, et al.. (2017). Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. Journal of Viral Hepatitis. 25(2). 134–143. 18 indexed citations

11.

Kao, Jia‐Horng, Rong‐Nan Chien, Ting‐Tsung Chang, et al.. (2016). A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver International. 36(8). 1101–1107. 22 indexed citations

12.

Sarrazin, Christoph, Hadas Dvory‐Sobol, Evguenia S. Svarovskaia, et al.. (2016). Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology. 151(3). 501–512.e1. 163 indexed citations

13.

Gane, Edward, Christian Schwabe, Robert H. Hyland, et al.. (2016). Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. Gastroenterology. 151(3). 448–456.e1. 50 indexed citations

14.

Everson, Gregory T., William Towner, Mitchell Davis, et al.. (2015). Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection. Annals of Internal Medicine. 4 indexed citations

15.

Rodríguez‐Torres, M., Anuj Gaggar, Gong Shen, et al.. (2015). Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1–4 in Patients Coinfected With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5). 543–549. 23 indexed citations

16.

Svarovskaia, Evguenia, Ross Martin, Krishna Chodavarapu, et al.. (2015). O063 : HCV reinfection cases in phase 3 studies of sofosbuvir. Journal of Hepatology. 62. S222–S223. 7 indexed citations

17.

Younossi, Zobair M., Elzafir Elsheikh, Maria Stepanova, et al.. (2015). Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. Journal of Viral Hepatitis. 22(12). 977–982. 16 indexed citations

18.

Nyberg, Lisa M., Jacob Lalezari, Liyun Ni, et al.. (2014). 239 Successful Retreatment With Sofosbuvir-Containing Regimens for HCV Genotype 2 or 3 Infected Patients Who Failed Prior Sofosbuvir Plus Ribavirin Therapy. Gastroenterology. 146(5). S–905. 2 indexed citations

19.

Brainard, Diana M., Evan Friedman, Bo Jin, et al.. (2010). Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics. The Journal of Clinical Pharmacology. 51(3). 422–427. 44 indexed citations

20.

Brainard, Diana M.. (2008). Doubling the Dose of Raltegravir (RAL) Does Not Increase Trough Levels in the Presence of Rifampin (RIF). 46th Annual Meeting. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact